- Home
- MDV vs RAPT Comparison
MDV vs RAPT Comparison
Compare MDV & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDV
- RAPT
- Stock Information
- Founded
- MDV 2015
- RAPT 2015
- Country
- MDV United States
- RAPT United States
- Employees
- MDV N/A
- RAPT N/A
- Industry
- MDV Transportation Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- MDV Consumer Discretionary
- RAPT Health Care
- Exchange
- MDV Nasdaq
- RAPT Nasdaq
- Market Cap
- MDV 147.6M
- RAPT 122.9M
- IPO Year
- MDV 2022
- RAPT 2019
- Fundamental
- Price
- MDV $14.27
- RAPT $8.04
- Analyst Decision
- MDV
- RAPT Buy
- Analyst Count
- MDV 0
- RAPT 5
- Target Price
- MDV N/A
- RAPT $42.00
- AVG Volume (30 Days)
- MDV 107.6K
- RAPT 109.8K
- Earning Date
- MDV 08-05-2025
- RAPT 08-07-2025
- Dividend Yield
- MDV 8.30%
- RAPT N/A
- EPS Growth
- MDV N/A
- RAPT N/A
- EPS
- MDV N/A
- RAPT N/A
- Revenue
- MDV $46,738,000.00
- RAPT N/A
- Revenue This Year
- MDV $2.21
- RAPT N/A
- Revenue Next Year
- MDV $4.45
- RAPT N/A
- P/E Ratio
- MDV N/A
- RAPT N/A
- Revenue Growth
- MDV N/A
- RAPT N/A
- 52 Week Low
- MDV $13.62
- RAPT $5.67
- 52 Week High
- MDV $18.11
- RAPT $30.60
- Technical
- Relative Strength Index (RSI)
- MDV 44.01
- RAPT 62.95
- Support Level
- MDV $14.01
- RAPT $7.04
- Resistance Level
- MDV $14.73
- RAPT $8.91
- Average True Range (ATR)
- MDV 0.31
- RAPT 0.84
- MACD
- MDV 0.02
- RAPT 0.08
- Stochastic Oscillator
- MDV 17.20
- RAPT 92.53
About MDV Modiv Industrial Inc. Class C
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.